Titan Pharmaceuticals, Inc.
TTNP
$3.70
-$0.09-2.38%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -100.00% | -98.99% | -81.25% | -66.85% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -100.00% | -98.99% | -81.25% | -66.85% |
| Cost of Revenue | -- | -83.03% | -73.03% | -65.40% | -59.77% |
| Gross Profit | -- | 81.01% | 69.57% | 63.26% | 58.83% |
| SG&A Expenses | -17.86% | -1.08% | 11.95% | -9.58% | -8.07% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -38.93% | -29.54% | -20.18% | -31.72% | -30.86% |
| Operating Income | 37.38% | 26.83% | 16.51% | 29.28% | 28.90% |
| Income Before Tax | 15.50% | 4.53% | 35.49% | 46.96% | 45.43% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 15.50% | 4.53% | 35.49% | 46.96% | 45.43% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 15.50% | 4.53% | 35.49% | 46.96% | 45.43% |
| EBIT | 37.38% | 26.83% | 16.51% | 29.28% | 28.90% |
| EBITDA | 36.47% | 25.49% | 15.18% | 28.61% | 28.63% |
| EPS Basic | 29.32% | 15.86% | 42.42% | 50.40% | 52.05% |
| Normalized Basic EPS | 46.28% | 33.88% | 22.01% | 32.34% | 36.92% |
| EPS Diluted | 29.32% | 15.86% | 42.42% | 50.40% | 52.05% |
| Normalized Diluted EPS | 46.28% | 33.88% | 22.01% | 32.34% | 36.92% |
| Average Basic Shares Outstanding | 19.51% | 15.05% | 10.32% | 7.22% | 11.99% |
| Average Diluted Shares Outstanding | 19.51% | 15.05% | 10.32% | 7.22% | 11.99% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |